Introduction {#sec1-2055207620936435}
============

Control of fertility, and feeling satisfied with a chosen method of contraception are crucial to the health and wellbeing of women, but unintended pregnancy remains common and costly for individuals and for health services. Globally, about 40% of pregnancies are estimated to be unplanned.^[@bibr1-2055207620936435]^ In Britain, around 45% of pregnancies are unplanned or ambivalent^[@bibr2-2055207620936435]^ despite a range of freely available effective contraceptive methods, and abortion rates in England and Wales have changed little since 2011.^[@bibr3-2055207620936435]^

Preventing unintended pregnancy involves many steps, including timely education, awareness and socially influenced behaviours to seek, choose and use contraception consistently and correctly.^[@bibr4-2055207620936435]^ Health services have a key role to play by supporting people to choose and use an appropriate method that best meets their needs, but many people are not aware of the range of different methods available to them.^[@bibr5-2055207620936435],[@bibr6-2055207620936435]^ The contraceptive pill and condoms are well known and widely used, but are not the most effective contraceptive methods. Long-acting reversible contraception (LARC), which includes intrauterine devices, intrauterine systems, implants and injections, are at least 20 times more effective than oral contraceptive pills and condoms^[@bibr7-2055207620936435],[@bibr8-2055207620936435]^ but these methods are less well known, and not all services have the capacity to fit them.^[@bibr9-2055207620936435]^

Increasingly women turn to online sources of information on sexual health,^[@bibr10-2055207620936435]^ but information is of variable quality and accuracy^[@bibr11-2055207620936435]^ and misperceptions about contraception are common.^[@bibr12-2055207620936435]^ Hormonal contraception methods have many potential benefits apart from control of fertility, including treatment of acne, reduced period pain, lighter periods or no withdrawal bleeds, and reduction in premenstrual symptoms,^[@bibr13-2055207620936435]^ but women may be more aware of risks and side effects than benefits of contraception.^[@bibr12-2055207620936435]^

Interactive (tailored) digital interventions are effective for increasing contraception knowledge^[@bibr14-2055207620936435]^ uptake of more effective contraceptive methods and contraception adherence,^[@bibr15-2055207620936435][@bibr16-2055207620936435]--[@bibr17-2055207620936435]^ and decreasing unplanned pregnancy.^[@bibr18-2055207620936435],[@bibr19-2055207620936435]^ Digital interventions offer the advantages of intervention content accuracy and fidelity, and the potential to reach large audiences with relatively low dissemination costs.^[@bibr20-2055207620936435]^ We therefore developed an interactive website to aid informed choice of contraceptive method and then conducted a randomised controlled trial to evaluate its impact in clinic populations.

Aim {#sec2-2055207620936435}
===

To assess the efficacy of the *Contraception Choices* website in comparison with control (waiting list) on uptake of long-acting contraceptive methods, and satisfaction with method choice in young women.

Methods {#sec3-2055207620936435}
=======

We conducted an individually randomised, parallel group-controlled trial that started as a feasibility trial and ended as an efficacy (clinical) trial. Approval was given by London Camden & Kings Cross Research Ethics Committee (Reference 17/LO/0112).

Summary of intervention development {#sec4-2055207620936435}
-----------------------------------

We conducted two systematic reviews of the literature to generate the evidence base for the website: a review of reviews of factors influencing contraception choice and use and a review of interactive digital interventions for contraception. To gain the views of contraceptive users, we recruited women from sites in London that represent the settings in which the great majority of contraceptive care occurs in the UK:^[@bibr21-2055207620936435]^ a general practice, two sexual health centres, an abortion clinic, a community pharmacy and an antenatal clinic. Eligibility criteria were women aged 15--30 years, ability to give informed consent, and interest in taking part in contraceptive research. We conducted focus groups and individual interviews to explore the views of 74 young women relating to contraception (access, acceptability, barriers, concerns, benefits and personal decisions around choices) and their views on website design and content. Working iteratively with the young women and a commercial software company (Moore Wilson), we synthesised the findings from the systematic reviews and qualitative research with women's views to develop a trial-ready, self-guided website offering tailored advice.

Intervention {#sec5-2055207620936435}
------------

The *Contraception Choices* website offers tailored information to help users to decide which method of contraception might suit them best, to facilitate informed choices, satisfaction with choice, and uptake of more effective methods (Logic Model, supplementary material). *Contraception Choices* provides information about contraception: videos of women and health professionals discussing contraceptive experiences, concerns and misperceptions; an infographic representing contraception effectiveness; *Did you Know?* and *Contraception FAQ* sections which address common concerns, and an interactive decision tool *What's right for me?* (See Supplementary file: Screenshots). The *What's right for me?* tool ([Figure 2](#fig2-2055207620936435){ref-type="fig"}) elicits seven individual priorities concerning contraception attributes. For example, selecting 'Regular periods' highlights methods compatible with regular periods (simultaneously fading out those that can alter the menstrual cycle) and the algorithm scores the highlighted methods more highly. Three methods most consistent with the individual's preferences are displayed and compared side-by-side, and the user can export their results by email or text message. [www.contraceptionchoices.org](http://www.contraceptionchoices.org) ([Figure 1a](#fig1-2055207620936435){ref-type="fig"} and [Figure 1b](#fig1-2055207620936435){ref-type="fig"}).

###### 

*Contraception Choices* website: home page.
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The website content and design is underpinned by a number of different theoretical principles including the following: **Human-centred design** and **collaboration with target users**-- we involved target users in content and design decisions, to ensure that content met young women's needs, priorities and preferences.^[@bibr20-2055207620936435]^**Tailoring** -- the *What's right for me?* decision tool offers tailored information on contraception method choices to increase relevance for more effective learning, engagement, and behaviour change.^[@bibr22-2055207620936435]^**Health belief model** -- the *Effectiveness* infographic addresses perceptions of risk of pregnancy, showing the relative effectiveness of different contraception methods.**Social cognitive theory** -- *Contraception Choices* videos draw on the influence of peers by featuring young women discussing their experiences of contraception including the potential benefits of different methods.The **COM B model: capability, opportunity, motivation-behaviour model**^[@bibr23-2055207620936435]^ -- this takes into account factors which are on pathways to behaviour change.A **social determinants of health framework**^[@bibr24-2055207620936435]^ underpins the design of two infographics which convey barriers to contraception use across different domains: individual women, partners, family, peers, community, health services and wider society.

Participants {#sec6-2055207620936435}
============

Inclusion criteria: women aged 15--30 years with a current or future need for contraception, attending one of the study sites, able to read English, with an active email account and access to the internet and willing to be followed up for 6 months. Exclusion criteria: unable to provide informed consent (e.g. severe learning difficulties) or need for a language advocate (because the intervention was intended to be accessed in private). At the sites described above, women waiting for their appointment (or in the pharmacy) were approached by a researcher with a 'tablet' computer and invited to take part in the trial. Women recruited via the online booking system were sent a text message inviting them to view the *Contraception Choices* website before their booked appointment. Those who expressed interest were recruited online via the tablet computer using software designed specifically for this trial, to confirm eligibility and register informed consent.

Procedures {#sec7-2055207620936435}
----------

Participants were asked to complete a short questionnaire at baseline which included demographic data (age, ethnicity, highest completed level of education) and whether English was their first language; current use of contraception, or reasons for non-use (including being pregnant); contraception method; from where the method was obtained, and whether it was free or paid for; satisfaction with current contraception (very satisfied, satisfied, neither satisfied or dissatisfied, dissatisfied and very dissatisfied); ever used contraceptive methods (same list as current use); and self-reported sexually transmitted infections in the last 3 months. Automated, computerised randomisation occurred immediately after baseline data collection.

Randomisation and masking {#sec8-2055207620936435}
-------------------------

A randomisation list was generated by a random number based algorithm in the computer software Stata^[@bibr25-2055207620936435]^ and incorporated into the trial software programme to allocate all participants to either the intervention or control group. The randomisation list was stratified by setting and used varying block sizes. Allocation was immediate (online) and concealed. Those randomised online to the intervention group gained access to the *Contraception Choices* website immediately; women randomised to the control group could access the website at the end of data collection, at which point we emailed them with a link to the website.

At 3 and 6 month follow-up, participants were emailed a short online survey asking what method of contraception they were using (including none) and how satisfied they were with the method; whether they had had a pregnancy and, if so, the outcome of the pregnancy (ongoing, gave birth, miscarried, terminated, or prefer not to say); and self-reported sexually transmitted infection in the previous 3 months.

All participants were asked whether they had visited the *Contraception Choices* website (control participants were asked in order to assess 'contamination') and asked a free-text question: "Has being in the study had any good or bad effects on your life?" Intervention group participants only were asked further questions about the website: how helpful it was in terms of 'getting useful information about contraception' and 'finding a method of contraception that is right for you' (five response options from very helpful to very unhelpful); whether they had discussed the website with anyone (including a doctor or nurse, pharmacist, partner, family or friends) and "What did you like or dislike about the website?" (as a free-text question).

Participants were sent electronic vouchers for completing follow-up surveys (£5 for the 3 month survey, £15 for the 6 month survey). All follow-up emails included a link to enable participants to withdraw from the study, including one sent immediately after enrolment.

The analysis of the primary outcomes was conducted blinded to allocation.

Outcomes -- original feasibility trial {#sec9-2055207620936435}
--------------------------------------

The primary outcome for the initial feasibility trial was follow-up rate at 6 months. Secondary outcomes at 6 months were: effectiveness of contraceptive method used, grouped from least to most effective as follows: no method, withdrawal or natural method, condoms or diaphragm, pill, patch or ring, LARC or sterilisation; change in effectiveness of method between baseline and 6 months; pregnancy and sexually transmitted infection.

Outcomes -- efficacy trial {#sec10-2055207620936435}
--------------------------

As we were developing *Contraception Choices*, its popularity with young women became very evident. Moreover, our presentations of the website to colleagues were met with demand to use it immediately in clinical practice. Future funding for a definitive trial was highly uncertain and withholding the website for a number of years, in order that a definitive trial with a control group of women who had not seen the website might be funded and completed, felt unpalatable. Fortunately, the opportunity arose to increase recruitment at minimal cost (see below) and so we were able to expand the feasibility trial into an efficacy trial by substituting the primary outcome (follow-up rate at 6 months) for two primary clinical outcomes that were originally secondary outcomes -- use of LARC at 6 months and satisfaction with contraceptive method at 6 months. (We pre-specified that we would consider the trial to have demonstrated superiority of the intervention if a statistically significant benefit were observed for one or both outcomes without clear evidence of harm for either). Secondary outcomes were effectiveness of contraceptive method at 6 months; change in method from baseline to 6 months; pregnancy by 6 months and diagnosed sexually transmitted infection reported at 3 or 6 months.

To increase recruitment for the efficacy trial, we took advantage of an online booking system for appointments at one site (sexual and reproductive health clinic) by adding a hyperlink about the trial into the text message that women received to confirm their contraception clinic appointment. Clicking on the hyperlink took them directly to the trial website for recruitment and randomisation.

Data analysis {#sec11-2055207620936435}
-------------

The original target sample size for the feasibility trial was 80 participants per setting, based on estimating a follow-up rate at 6 months of 70% to within 10% precision (95% CI 60% to 80%) for each setting. Changing the design to a clinical efficacy trial resulted in a total sample size of 930 participants, based on the power to assess the effect of the intervention on the revised primary outcome, use of LARC at 6 month follow-up. Specifically, assuming a follow-up rate of 70%, this sample size provides at 82% power to detect as significant (at the 5% level) an increase from 35% (control group prevalence) to 47% in LARC use in the intervention group. No formal sample size calculation was made for the other primary outcome. The standard 5% significance level was taken because although there are two primary outcomes we use results from both to assess whether the intervention is beneficial.

The primary analysis was by modified intention-to-treat, basing analysis on those who completed at least one follow-up outcome questionnaire. For each primary and secondary outcome listed earlier we present the percentage of participants if the outcome is binary (e.g. use of LARC) or ordinal (e.g. effectiveness of method, satisfaction with method) together with a 95% confidence interval. These percentages and means are reported separately by intervention and standard care arm. To formally assess differences between arms we used logistic regression (for binary outcomes), or ordinal logistic regression (for ordinal outcomes), reporting adjusted odds ratios with 95% confidence intervals.

The primary outcome of LARC use at 6 months was analysed among women in need of contraception (i.e. not pregnant or currently trying to become pregnant) and the primary outcome of satisfaction with method was analysed among women who were using a method at 6 months. The primary outcome of LARC use at 6 months was analysed stratified by LARC use at baseline, leading to three intervention effects: the effect in baseline LARC users, the effect in baseline non-users, and the overall effect adjusted for baseline LARC use. We pre-specified that if fewer than 90% of baseline LARC users in the control arm are using a LARC method at 6 months, then the primary effect measure would be the overall adjusted intervention effect, and otherwise (due to limited scope for increase in baseline LARC users) the primary effect measure would be the effect in baseline non-users only. Besides adjustment for baseline LARC use, analysis of both primary outcomes was also adjusted for satisfaction with method at baseline and by setting. A further subgroup analysis, based on testing an interaction term, was conducted for both primary outcomes to assess whether the effect of the intervention varies by setting (specifically between online and in-person recruitment). Comparisons for the primary outcomes between arms were based on multiple imputation where the primary outcomes at 6 months were imputed based on the outcomes at 3 months for participants who completed the 3 month outcome questionnaire but failed to complete the questionnaire at 6 months. Imputation was conducted using the chained equations approach and implemented using the mi impute function,^[@bibr10-2055207620936435]^ twenty imputed datasets were generated. Considering our secondary outcomes, analysis of contraceptive effectiveness was restricted to women in need of contraception at 6 months, reporting of a change in method was restricted to women in need of contraception at both baseline and 6 months, and analysis of pregnancy at 6 months was restricted to women who were not pregnant or trying for a baby at baseline. All analysis was conducted in Stata 15 software.

A post hoc decision was made to conduct a 'per-protocol' analysis for the primary outcomes based on a comparison of intervention arm participants who reported seeing the *Contraception Choices* website with all control arm participants.

All free-text comments from the 3 month and 6 month trial follow up surveys were imported into NVIVO software, and coded. We used thematic analysis to identify patterns and links across the data set. Two researchers (AG and JAS) independently coded the data, categorised data by theme, and identified relationships between concepts to develop a coding frame. Coding decisions were reviewed by a third researcher (JB).

Role of the funding source {#sec12-2055207620936435}
--------------------------

The funding source had no role in the writing of the manuscript or the decision to submit it for publication.

Results {#sec13-2055207620936435}
=======

Recruitment and follow-up {#sec14-2055207620936435}
-------------------------

The first participant was randomised on 4 July 2017 and the last on 22 December 2017. The first recruitment through the online booking service was on 31 October and the last on 22 December 2017. Recruitment online was much faster than in the clinics. It took approximately 6 months to recruit 419 women from the clinic sites, and just over seven weeks to recruit 508 women via the online booking system ([Table 1](#table1-2055207620936435){ref-type="table"}).

###### 

Baseline characteristics by study arm.

![](10.1177_2055207620936435-table1)

  Characteristic, % (n)                               Intervention, N = 464   Control, N = 463
  --------------------------------------------------- ----------------------- ------------------
  **Site of recruitment**                                                     
   Sexual and reproductive health clinic              8.6 (40)                8.4 (39)
   General practice                                   7.3 (34)                8.2 (38)
   Abortion service                                   4.5 (21)                4.8 (22)
   Maternity service                                  8.4 (39)                8.6 (40)
   Community pharmacy                                 6.9 (32)                7.1 (33)
   Sexual Health clinic for young people              8.8 (41)                8.6 (40)
   Direct online booking (for the SRH clinic above)   55.4 (257)              54.2 (251)
  **Demographic factors**                                                     
  Age, median (IQR)                                   24 (21--27)             24 (21--27)
  Ethnicity                                                                   
   White                                              67.0 (306)              71.0 (326)
   Mixed                                              11.6 (53)               10.5 (48)
   Asian                                              10.3 (47)               8.1 (37)
   Black                                              9.0 (41)                8.3 (38)
   Other                                              2.2 (10)                2.2 (10)
  First language                                                              
   English                                            80.8 (375)              84.2 (390)
   Not English                                        19.2 (89)               15.8 (73)
  Highest completed level of education                                        
   Degree                                             51.3 (238)              49.9 (231)
   Diploma in higher education                        10.6 (49)               9.7 (45)
   A/AS levels                                        21.3 (99)               23.5 (109)
   O levels / GCSE                                    9.7 (45)                7.8 (36)
   Other                                              5.4 (25)                5.8 (27)
   None                                               1.7 (8)                 3.2 (15)
  **Contraception factors**                                                   
  Need for contraception                                                      
   No -- Pregnant                                     9.7 (45)                10.6 (49)
   No -- Trying for baby                              0.2 (1)                 0.2 (1)
   Yes -- Neither                                     90.1 (418)              89.2 (413)
  Method used, if needed, ordered by efficacy                                 
   None                                               17.7 (74)               18.6 (77)
   Unclear                                            0.2 (1)                 0.5 (2)
   Withdrawal/natural                                 0 (0)                   1.2 (5)
   Condom/diaphragm                                   10.5 (44)               11.1 (46)
   Pill/patch/ring                                    42.6 (178)              39.0 (161)
   LARC/sterilisation                                 29.0 (121)              29.5 (122)
  Satisfaction with method, if using a method                                 
   Very dissatisfied                                  4.3 (15)                3.3 (11)
   Dissatisfied                                       11.6 (40)               12.2 (41)
   Neutral                                            16.2 (56)               17.2 (58)
   Satisfied                                          36.4 (126)              32.6 (110)
   Very satisfied                                     31.5 (109)              34.7 (117)

LARC: long-acting reversible contraception

The last follow-up survey was completed on 16 August 2018. The CONSORT diagram ([Figure 2](#fig2-2055207620936435){ref-type="fig"}) details the flow of participants through the trial. In total, 927 women were randomised to the website (n = 464) or to control group (n = 463) of whom 739 (80%) provided follow-up data at 6 months, and 786 women (86%) provided data at 3 and/or 6 months for analysis of primary outcomes with imputation.

![CONSORT diagram.](10.1177_2055207620936435-fig2){#fig2-2055207620936435}

Follow-up rates were similar across all sites (data not shown) except for the abortion service, where the follow-up rate was only 50%. The quality of the follow up survey data collected was very high, with all respondents providing the primary outcome data. Eighteen (2%) women (11 in the intervention group and 7 in the control group) withdrew from the trial without offering reasons but they did not request that their data be withdrawn from analysis.

The proportion of women who reported that they had seen the *Contraception Choices* website at any time during the trial was 86% in the intervention group and 7% in the control group, indicating good exposure in the intervention group and little 'contamination' in the control group.

Baseline data {#sec15-2055207620936435}
-------------

Just over two-thirds of participants were from White ethnic groups, half were educated to degree level and four-fifths reported English as their first language ([Table 1](#table1-2055207620936435){ref-type="table"}). Ten percent were pregnant at enrolment, while 90% indicated a current need for contraception to avoid unintended pregnancy. The most common method reported at baseline was the oral contraceptive pill at 39.5% (n = 167) in the intervention group and 34.6% (n = 146) in the control group, followed by LARC methods ([Table 1](#table1-2055207620936435){ref-type="table"}). Around two-thirds of women were satisfied with their current method at baseline. (Only one woman reported being sterilised at baseline; she is not included in subsequent analysis because she did not complete a follow-up.)

Primary outcomes {#sec16-2055207620936435}
----------------

There were no significant difference between intervention and control groups in the proportion of women using LARC at 6 months \[30.4% intervention *versus* 31.0% control; adjusted odds ratio after imputation 0.87 (95% confidence interval 0.60--1.28)\], or in level of satisfaction with contraceptive method \[proportion being 'satisfied' or 'very satisfied' 82.6% intervention *versus* 82.1% control; adjusted ordinal odds ratio after imputation 0.93 (95% CI 0.69--1.25) based on the five ordered responses\].

Around half of the participants in each group changed their method of contraception between baseline and 6 months; the most common change was to a more effective method (24% intervention group; 21% control) but 19% in the intervention group and 16% in the control group changed to a less effective method ([Table 2](#table2-2055207620936435){ref-type="table"}). Among women who were using LARC at baseline, the proportion using LARC at 6 months was significantly higher in the control group than the intervention group ([Table 2](#table2-2055207620936435){ref-type="table"}). Among participants not using LARC at baseline, there was a non-significantly higher proportion using LARC at 6 months in the intervention group. Across both study arms, satisfaction with method of contraception improved from around two-thirds at baseline to four-fifths at follow-up. There was no difference between groups in the proportion of women who were pregnant at 6 months (among women who were neither pregnant nor trying for a baby at baseline) or the proportion who reported a diagnosed sexually transmitted infection (STI) at 3 or 6 months ([Table 2](#table2-2055207620936435){ref-type="table"}).

###### 

Comparison of outcomes between arms.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome measures, % (n)                                         Intervention   Control      OR (CI), Intervention vs. control   Adjusted OR (CI)
  --------------------------------------------------------------- -------------- ------------ ----------------------------------- ----------------------
  **Primary outcomes**                                                                                                            

  **LARC method in use at 6 months**, overall N = 713^1^          30.4 (106)     31.0 (113)   *p = 0.74*\                         *p = 0.48*\
                                                                                              0.95 (0.69--1.30)                   0.87 (0.60--1.28)^6^

   If using LARC at baseline, N = 201                             58.8 (57)      70.2 (73)    *p = 0.12*\                         *p = 0.024*\
                                                                                              0.63 (0.35--1.12)                   0.46 (0.23--0.90)^7^

   If not using LARC at baseline, N = 512                         19.4 (49)      15.4 (40)    *p = 0.40*\                         *p = 0.49*\
                                                                                              1.22 (0.77--1.92)                   1.18 (0.74--1.90)^7^

  **Satisfaction with method used at 6 months**, N = 624^2^                                                                       

   Very dissatisfied                                              1.9 (6)        1.6 (5)                                          

   Dissatisfied                                                   4.2 (13)       5.8 (18)     *p = 0.54*                          *p = 0.62*

   Neutral                                                        11.3 (35)      10.5 (33)    0.91 (0.68--1.22)                   0.93 (0.69--1.25)^6^

   Satisfied                                                      39.9 (124)     35.5 (111)                                       

   Very satisfied                                                 42.8 (133)     46.7 (146)                                       

  **Secondary outcomes**                                                                                                          

  Effectiveness of contraceptive method at 6 months, N = 713^1^                                                                   

   None                                                           10.9 (38)      14.0 (51)                                        

   Withdrawal/natural                                             1.7 (6)        1.4 (5)      *p = 0.63*                          *p = 0.33*

   Condom/diaphragm                                               12.6 (44)      12.1 (44)    1.07 (0.82--1.40)                   1.15 (0.87--1.52)^8^

   Pill/patch/ring                                                44.4 (155)     41.5 (151)                                       

   LARC/sterilisation                                             30.4 (106)     31.0 (113)                                       

  Change in method from baseline to 6 months, N = 651^3^                                                                          

   Change to more effective                                       23.8 (76)      20.5 (68)                                        

   Change to similarly effective                                  11.3 (36)      12.7 (42)    N/A                                 N/A

   No change                                                      46.3 (148)     51.1 (169)                                       

   Change to less effective                                       18.8 (60)      15.7 (52)                                        

  Pregnancy by 6 months, N = 670^4^                               3.3 (11)       4.1 (14)     *p = 0.66*\                         *p = 0.76*\
                                                                                              0.86 (0.43--1.69)                   0.90 (0.45--1.79)^9^

  STI diagnosis reported at 3 or 6 months, N = 624^5^             5.3 (16)       4.7 (15)     *p = 0.76*\                         *p = 0.72*\
                                                                                              1.12 (0.55--2.31)                   1.14 (0.55--2.36)^9^
  ------------------------------------------------------------------------------------------------------------------------------------------------------

LARC: long-acting reversible contraception

Analysis restricted to the following subgroups as indicated

1\. Not pregnant or trying for baby at 6 months

2\. Using a method at 6 months

3\. Not pregnant or trying for baby at baseline or 6 months, clear reporting of method at both time points

4\. Not pregnant or trying for baby at baseline

5\. Completed 3 and 6 month questionnaire items

Adjusted for the following baseline factors as indicated

6\. LARC use, satisfaction with method, and setting

7\. satisfaction with method and setting

8\. effectiveness of method, satisfaction with method, and setting

9\. effectiveness of method

The effects of the intervention on the primary outcomes did not vary significantly between online and in-person recruitment (data not shown). Post hoc, per-protocol analysis of the primary outcomes was not appreciably different to the modified intention-to-treat analysis ([Table 3](#table3-2055207620936435){ref-type="table"}).

###### 

Post hoc per-protocol analysis of primary outcomes.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome measures, % (n)                                     Intervention (seen website)   Control (all)   OR (CI), Intervention vs. control   Adjusted OR (CI)\*
  ----------------------------------------------------------- ----------------------------- --------------- ----------------------------------- --------------------
  **LARC method in use at 6 months**, N = 660^1^              31.4 (93)                     31.0 (113)      *p = 0.86*\                         *p = 0.98*\
                                                                                                            1.03 (0.74--1.44)                   0.99 (0.66--1.49)

  **Satisfaction with method used at 6 months**, N = 578^2^                                                                                     

   Very dissatisfied                                          1.1 (3)                       1.6 (5)                                             

   Dissatisfied                                               4.2 (11)                      5.8 (18)        *p = 0.87*                          *p = 0.95*

   Neutral                                                    10.9 (29)                     10.5 (33)       0.97 (0.72--1.33)                   1.01 (0.74--1.39)

   Satisfied                                                  39.3 (104)                    35.5 (111)                                          

   Very satisfied                                             44.5 (118)                    46.7 (146)                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

LARC: long-acting reversible contraception.

Analysis restricted to the following subgroups as indicated.

1\. Not pregnant or trying for baby at 6 months.

2\. Using a method at 6 months.

\* Adjusted for LARC use at baseline, satisfaction with method at baseline, and setting.

Women's views of the Contraception Choices website {#sec17-2055207620936435}
--------------------------------------------------

Of the 364 intervention participants with 6-month follow-up data, 309 (85%) reported seeing the *Contraception Choices* website. Of those, 97% found it helpful or very helpful for "getting useful information about contraception" and 87% responded that it was helpful or very helpful for "finding a method of contraception that is right for you."

Over 91% (423/464) of intervention participants provided free-text comments about the website in follow-up surveys. Comments were strikingly positive, with praise for attractive website design, and the clarity of information presented. Analysis of the free-text comments indicated that the *Contraception Choices* website helped to increase participant's knowledge about contraceptive methods and address their concerns, helped with thinking about changing to a different method, and feeling better prepared before clinic appointments.

Knowledge about different methods {#sec18-2055207620936435}
=================================

Women liked information which helped them to weigh up the advantages and disadvantages of different methods:""Gives you the ups and downs about each choice and also helps advise which one to choose.""""I feel more clued up about potential contraception choices which is great! I think far too many think that the pill is the only way forward which is wrong!""

Tailored information {#sec19-2055207620936435}
====================

Women valued tailored feedback such as the *What's right for me?* decision aid, to help them to choose contraceptive methods to suit their priorities.""It's what I've always looked for, a clear way to compare methods of contraception and find the best for you... It may seem crazy, but it's really hard to find reliable and objective facts on contraception online.""""I liked how easy it was to tailor a contraception to you and that it considered things like not wanting a period.""

Concerns and misperceptions {#sec20-2055207620936435}
===========================

Many women appreciated information which addressed concerns and misperceptions, which was not necessarily easy to find elsewhere:""I was particularly interested in reading that you don't need a break from hormonal contraception.""""It's cleared up some of my doubts and things I worried about (probably unconsciously!) about hormonal contraception.""""Really useful, accessible information covering concerns that you wouldn't normally see on a medical website, like... specifically stopping periods.""

Prompting changes of contraceptive method {#sec21-2055207620936435}
=========================================

Several participants discussed their intention to change or consider swapping to a new method as a result of what they had learned or seen on the website. Of those who commented, all were thinking of switching to a more effective long-acting reversible contraceptive method.""I think it's (the website) got me thinking more about which contraception I should use. I'm quite happy with my pill and currently not sexually active, but I do think I would like to switch to a LARC if I am in a relationship again.""

Feeling empowered to speak to health professionals and more prepared before clinic appointments {#sec22-2055207620936435}
===============================================================================================

Many participants reported feeling more empowered to speak to healthcare professionals about contraception and feeling better prepared for appointments to discuss contraception:""It has made me feel more confident. Prior I didn't really have anyone to speak to about contraception and I didn't feel comfortable discussing it with my doctors so this bridged the gap.""""It has led to an increased conversation with my GP practice regarding suitable alternative methods to the combined pill.""""I think it's really good to go in \[to an appointment\] prepared with what you've looked at and have an idea in your head before you make a decision about it.""

Barriers to accessing chosen contraception methods {#sec23-2055207620936435}
==================================================

Although some participants wanted to change to a more effective method of contraception, there were a number of reported barriers to accessing contraception.""I wanted the coil but I found it difficult to find someone to fit it in London.""""Long waiting times. GP did not offer the services to get implant fitted. Lack of sexual health clinics in my area means very long waiting times.""

Neutral or negative comments {#sec24-2055207620936435}
============================

There were only 12 neutral or negative comments, often from women who gave positive comments too, such as:""Positive: easy to navigate, clear concise bullet points for advantages/disadvantages of each contraceptive method. Negative: no information relating to contraception as a treatment for endometriosis.""

Five negative comments were from women who wanted more specific information about particular contraceptive methods, and one person sought information about handling difficult conversations with general practitioners.

Discussion {#sec25-2055207620936435}
==========

In this randomised trial of the *Contraception Choices* website, we did not find significant differences between intervention and control groups in use of LARC or satisfaction with contraceptive method by 6 months. There were no significant differences in reported adverse effects, including pregnancy and STI diagnoses. The *Contraception Choices* website was very positively evaluated by young women, who indicated that it helped them to learn about contraception, to think about changing to a different method, and to feel better prepared before clinic appointments. However, difficulty accessing health services is an important barrier to accessing chosen methods of contraception.

Globally, there are an estimated 1.7 billion women of reproductive age (15--49 years).^[@bibr26-2055207620936435]^ Ensuring access to accurate information about contraception to facilitate informed decisions about choice and use of contraception is an essential but challenging step towards prevention of unintended pregnancy.^[@bibr27-2055207620936435],[@bibr28-2055207620936435]^ This paper describes the evaluation of *Contraception Choices*, an interactive website to aid informed choice of contraception. The evidence base for the website came from extensive systematic review of published literature and empirical qualitative research with young women, and the intervention is underpinned by behaviour change theory. The evaluation method was unusually rigorous for a website -- according to recent NICE guidance, a randomised trial is the standard reserved for digital health technologies that aim to prevent and manage disease.^[@bibr29-2055207620936435]^

The women who took part in the trial broadly reflect the ethnic diversity of London,^[@bibr30-2055207620936435]^ the proportion of graduates^[@bibr31-2055207620936435]^ and the proportion of people whose main language is English in the UK.^[@bibr32-2055207620936435]^ At the outset, we did not expect to complete an efficacy (Phase III) trial of the website, but the demand for *Contraception Choices* from service providers, combined with the opportunity to rapidly expand recruitment and enlarge the trial, led to the transition from a feasibility to an efficacy trial. Aside from delays due to the lengthy process of obtaining all research permissions, the study procedures overall worked well, the online trial processes were highly efficient and the follow-up rate was good, with 86% of participants providing primary outcome data at 3 or 6 months. Recruitment in person was completed within the anticipated 6 months, but recruiting online (via the online booking system) was much more efficient, being faster and at no additional cost. Just over half of all participants were recruited this way in less than eight weeks.

Our study underscores other evidence that online trials are an efficient and acceptable way to conduct clinical trials of low-risk interventions.^[@bibr33-2055207620936435]^ However, choice of methodology and appropriate time-scale for evaluating the impact of digital health interventions remains a key question; guidance on evaluation of complex interventions from the UK Medical Research Council,^[@bibr34-2055207620936435]^ for example, with its meticulous but slow progression through development, feasibility, evaluation and implementation, seems out of step with the rapid pace of change in digital health.

Digital interventions such as *Contraception Choices* can meet a need for convenient, trustworthy online information and support for contraception decision-making.^[@bibr35-2055207620936435],[@bibr36-2055207620936435]^ Our findings clearly show that the website was popular and well received by users and healthcare providers. Given the strikingly positive feedback about the website from women, the high level of intervention engagement (over four-fifths viewed the website) and low 'contamination' in the control group (only 7% of the control group reported seeing the website), the lack of difference in primary outcomes between groups was surprising.

Possible reasons for the observed lack of impact relate to the many influences on contraceptive use which are beyond an individual woman's control,^[@bibr4-2055207620936435]^ for example, the opinions of partners, peers, religious leaders and the wider community,^[@bibr4-2055207620936435],[@bibr37-2055207620936435]^ and barriers to accessing services for a desired method, including difficulties in getting appointments, long waiting times and a lack of services that can fit LARC methods. Other possible explanations include needing longer follow-up for intentions to translate into action; measurement reactivity (i.e. the possible impact of asking the control group about their contraception use); the limitations of a broad outcome measure like 'satisfaction with method'; the possibility that both intervention and control group were receiving high quality clinical care; and nearly a third were already using LARC methods at baseline so that the website could not show an additional impact. With hindsight, we might have seen significant differences between groups had we included intermediate outcomes, such as 'feeling better informed about choice of methods' or 'feeling confident about discussing different contraceptive methods with a health professional', but ultimately, clinically important outcomes are the number of women using an effective contraceptive method that they are happy with and the prevention of unwanted pregnancy.

In terms of implementing digital health interventions in NHS services, we found that directing patients to the *Contraception Choices* website via an automated text message to confirm a clinic appointment was simple and effective, without additional cost. Offering the link at the time of booking an appointment facilitates access to the website well before a contraceptive consultation and some women commented that they felt better prepared for their consultation as a result. The *Contraception Choices* website was offered for self-directed use before appointments (in clinic settings or at home), but the website could also be jointly accessed during consultations. For example, the three tailored contraception options generated by the *What's right for me?* feature can be discussed with clinicians, and the website can also be displayed on the health professional's computer screen during consultations. In this study, we did not aim to assess such a development in clinical practice, but an area for future research is to examine whether it could lead to more efficient or satisfying consultations, for both patients and clinicians, with potentially better clinical or health service outcomes.^[@bibr38-2055207620936435]^ Electronic interventions for contraception which offer tailored material, increased frequency of intervention administration, and/or structured follow-up with a healthcare provider appear important for longer-term impact:^[@bibr35-2055207620936435]^ high quality evidence is needed on the effectiveness of different intervention designs, and cost-effectiveness of different models of intervention delivery.

*Contraception Choices* is currently attracting over 15,000 visits a month and is promoted via a link on the NHS website^[@bibr39-2055207620936435]^ which receives around 11 million visits per year. The availability of the website on the internet offers many possibilities for further use and evaluation. In our systematic review, we found remarkable consistency across the globe in factors influencing contraception choice, uptake and use. With appropriate adaptations, Contraception Choices may be of benefit to populations in different settings (e.g. schools) or different countries; we are currently exploring its utility in Botswana, a country with advanced e-health capacity and high HIV prevalence. We see a real opportunity to use *Contraception Choices* with vulnerable populations, including those where information and education to support effective use of contraception are scarce.

In conclusion, the *Contraception Choices* website was very popular with young women for its attractive design, engaging presentation of trustworthy information, and guidance in choosing a method tailored to individual preferences. However, we did not find any significant difference in use of LARC or satisfaction with contraceptive method at 6 months. Our systematic reviews confirmed multiple factors affecting women's choice and use of contraception which go beyond informed choice, such as the influence of others including partners, friends, family, school, religion, wider culture and health services. The lack of effect on clinical outcomes in this trial, despite highly positive feedback from participants, highlights a gap between improving delivery of personalised information and impact on contraceptive use. An interactive website can address individual barriers to contraception choice and use such as lack of knowledge, concerns and misunderstandings, but interventions at other levels are needed to complement this approach.
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